M&A Deal Summary

Hovione Acquires ExtremoChem

On November 16, 2023, Hovione acquired life science company ExtremoChem

Acquisition Highlights
  • This is Hovione’s 1st transaction in the Life Science sector.
  • This is Hovione’s 1st transaction in Portugal.

M&A Deal Summary
Date 2023-11-16
Target ExtremoChem
Sector Life Science
Buyer(s) Hovione
Deal Type Add-on Acquisition

Target

ExtremoChem

Lisboa, Portugal
ExtremoChem is a chemical synthesis company focused on the development of organic synthetic sugars for the stabilization of biologicals under stress conditions. ExtremoChem is based in Lisbon, Portugal.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Hovione

Loures, Portugal
Category Company
Founded 1959
Sector Life Science
DESCRIPTION

Hovione is a contract development and manufacturing organization (CDMO) it has a fully integrated offering of services for drug substances, drug product intermediates and drug products. The company has four FDA-inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione provides pharmaceutical customers services for the development and compliant manufacture of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. Hovione was founded in 1959 and is based in Loures, Portugal.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Portugal) 1 of 1
Year (2023) 1 of 1
Mergr

Product

Company

Legal